Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro.

Petersen EW, Carey AL, Sacchetti M, Steinberg GR, Macaulay SL, Febbraio MA, Pedersen BK.

Am J Physiol Endocrinol Metab. 2005 Jan;288(1):E155-62. Epub 2004 Sep 21.

2.

On the suppression of plasma nonesterified fatty acids by insulin during enhanced intravascular lipolysis in humans.

Carpentier AC, Frisch F, Cyr D, Généreux P, Patterson BW, Giguère R, Baillargeon JP.

Am J Physiol Endocrinol Metab. 2005 Nov;289(5):E849-56. Epub 2005 Jun 21.

3.

Recombinant human interleukin-6 infusion during low-intensity exercise does not enhance whole body lipolysis or fat oxidation in humans.

Hiscock N, Fischer CP, Sacchetti M, van Hall G, Febbraio MA, Pedersen BK.

Am J Physiol Endocrinol Metab. 2005 Jul;289(1):E2-7. Epub 2005 Mar 1.

4.

IL-6 selectively stimulates fat metabolism in human skeletal muscle.

Wolsk E, Mygind H, Grøndahl TS, Pedersen BK, van Hall G.

Am J Physiol Endocrinol Metab. 2010 Nov;299(5):E832-40. doi: 10.1152/ajpendo.00328.2010. Epub 2010 Sep 7.

5.

Additive effects of cortisol and growth hormone on regional and systemic lipolysis in humans.

Djurhuus CB, Gravholt CH, Nielsen S, Pedersen SB, Møller N, Schmitz O.

Am J Physiol Endocrinol Metab. 2004 Mar;286(3):E488-94. Epub 2003 Nov 4.

6.

High-fat diet elevates resting intramuscular triglyceride concentration and whole body lipolysis during exercise.

Zderic TW, Davidson CJ, Schenk S, Byerley LO, Coyle EF.

Am J Physiol Endocrinol Metab. 2004 Feb;286(2):E217-25. Epub 2003 Oct 14.

7.

Inhibition of adipose tissue lipolysis increases intramuscular lipid and glycogen use in vivo in humans.

van Loon LJ, Thomason-Hughes M, Constantin-Teodosiu D, Koopman R, Greenhaff PL, Hardie DG, Keizer HA, Saris WH, Wagenmakers AJ.

Am J Physiol Endocrinol Metab. 2005 Sep;289(3):E482-93. Epub 2005 May 10.

8.

Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes.

Kashyap SR, Belfort R, Berria R, Suraamornkul S, Pratipranawatr T, Finlayson J, Barrentine A, Bajaj M, Mandarino L, DeFronzo R, Cusi K.

Am J Physiol Endocrinol Metab. 2004 Sep;287(3):E537-46. Epub 2004 May 4.

9.

Effect of rhIL-6 infusion on GH-->IGF-I axis mediators in humans.

Nemet D, Eliakim A, Zaldivar F, Cooper DM.

Am J Physiol Regul Integr Comp Physiol. 2006 Dec;291(6):R1663-8. Epub 2006 Jul 13.

10.

Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients.

Gastaldelli A, Casolaro A, Ciociaro D, Frascerra S, Nannipieri M, Buzzigoli E, Ferrannini E.

Am J Physiol Endocrinol Metab. 2009 Jul;297(1):E225-30. doi: 10.1152/ajpendo.90960.2008. Epub 2009 May 5.

11.

A circadian rhythm in lipid mobilization which is altered in IDDM.

Hagström-Toft E, Bolinder J, Ungerstedt U, Arner P.

Diabetologia. 1997 Sep;40(9):1070-8.

PMID:
9300244
12.

Plasma adiponectin is modestly decreased during 24-hour insulin infusion but not after inhibition of lipolysis by Acipimox.

Dullaart RP, Riemens SC, Meinardi JR, Wolffenbuttel BH, Sluiter WJ.

Scand J Clin Lab Invest. 2005;65(6):523-31.

PMID:
16179286
13.

Cold stress increases lipolysis, FFA Ra and TG/FFA cycling in humans.

Vallerand AL, Zamecnik J, Jones PJ, Jacobs I.

Aviat Space Environ Med. 1999 Jan;70(1):42-50.

PMID:
9895020
14.

Post-exercise abdominal, subcutaneous adipose tissue lipolysis in fasting subjects is inhibited by infusion of the somatostatin analogue octreotide.

Enevoldsen LH, Polak J, Simonsen L, Hammer T, Macdonald I, Crampes F, de Glisezinski I, Stich V, Bülow J.

Clin Physiol Funct Imaging. 2007 Sep;27(5):320-6.

PMID:
17697029
15.

Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity.

Krag MB, Nielsen S, Guo Z, Pedersen SB, Schmitz O, Christiansen JS, Jørgensen JO.

Clin Endocrinol (Oxf). 2008 Sep;69(3):452-61. doi: 10.1111/j.1365-2265.2008.03231.x. Epub 2008 Mar 10.

PMID:
18331610
16.

Lipolytic and metabolic response to glucagon in fasting king penguins: phase II vs. phase III.

Bernard SF, Thil MA, Groscolas R.

Am J Physiol Regul Integr Comp Physiol. 2003 Feb;284(2):R444-54. Epub 2002 Oct 10.

17.

Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control.

Ahn CW, Kim CS, Nam JH, Kim HJ, Nam JS, Park JS, Kang ES, Cha BS, Lim SK, Kim KR, Lee HC, Huh KB.

Clin Endocrinol (Oxf). 2006 Apr;64(4):444-9.

PMID:
16584518
18.

Atrial natriuretic peptide contribution to lipid mobilization and utilization during head-down bed rest in humans.

Moro C, Pillard F, de Glisezinski I, Crampes F, Thalamas C, Harant I, Marques MA, Lafontan M, Berlan M.

Am J Physiol Regul Integr Comp Physiol. 2007 Aug;293(2):R612-7. Epub 2007 Jun 6.

19.

Real-time assessment of postprandial fat storage in liver and skeletal muscle in health and type 2 diabetes.

Ravikumar B, Carey PE, Snaar JE, Deelchand DK, Cook DB, Neely RD, English PT, Firbank MJ, Morris PG, Taylor R.

Am J Physiol Endocrinol Metab. 2005 Apr;288(4):E789-97. Epub 2004 Nov 30.

20.

Mechanism of insulin-stimulated clearance of plasma nonesterified fatty acids in humans.

Carpentier AC, Frisch F, Brassard P, Lavoie F, Bourbonnais A, Cyr D, Giguère R, Baillargeon JP.

Am J Physiol Endocrinol Metab. 2007 Mar;292(3):E693-701. Epub 2006 Oct 24.

Supplemental Content

Support Center